Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells

Rachel M.Gibbons Johnson, Haidong M Dong

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/ PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.

Original languageEnglish (US)
Article number961
JournalFrontiers in Immunology
Volume8
Issue numberAUG
DOIs
StatePublished - Aug 10 2017

Fingerprint

CD80 Antigens
T-Lymphocytes
Neoplasms
Antibodies
Therapeutics
Allergy and Immunology
Patient Selection
Immunity
Cell Death
Biomarkers
Ligands

Keywords

  • B7-H1 (programmed death-ligand 1)
  • CTL
  • Immunotherapy
  • Programmed death-1:programmed death-ligand 1 blockade
  • T cells
  • Tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells. / Johnson, Rachel M.Gibbons; Dong, Haidong M.

In: Frontiers in Immunology, Vol. 8, No. AUG, 961, 10.08.2017.

Research output: Contribution to journalReview article

@article{5ab749697d6948e98befe8f168830fb7,
title = "Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells",
abstract = "The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/ PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.",
keywords = "B7-H1 (programmed death-ligand 1), CTL, Immunotherapy, Programmed death-1:programmed death-ligand 1 blockade, T cells, Tumor",
author = "Johnson, {Rachel M.Gibbons} and Dong, {Haidong M}",
year = "2017",
month = "8",
day = "10",
doi = "10.3389/fimmu.2017.00961",
language = "English (US)",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells

AU - Johnson, Rachel M.Gibbons

AU - Dong, Haidong M

PY - 2017/8/10

Y1 - 2017/8/10

N2 - The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/ PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.

AB - The programmed death-1 (PD-1) and its ligand PD-L1 (B7-H1) signaling pathway has been the focus of much enthusiasm in the fields of tumor immunology and oncology with recent FDA approval of the anti-PD-1 antibodies pembrolizumab and nivolumab and the anti-PD-L1 antibodies durvalumab, atezolimuab, and avelumab. These therapies, referred to here as PD-L1/ PD-1 checkpoint blockade therapies, are designed to block the interaction between PD-L1, expressed by tumor cells, and PD-1, expressed by tumor-infiltrating CD8+ T cells, leading to enhanced antitumor CD8+ T cell responses and tumor regression. The influence of PD-L1 expressed by tumor cells on antitumor CD8+ T cell responses is well characterized, but the impact of PD-L1 expressed by immune cells has not been well defined for antitumor CD8+ T cell responses. Although PD-L1 expression by tumor cells has been used as a biomarker in selection of patients for PD-L1/PD-1 checkpoint blockade therapies, patients whose tumor cells lack PD-L1 expression often respond positively to PD-L1/PD-1 checkpoint blockade therapies. This suggests that PD-L1 expressed by non-malignant cells may also contribute to antitumor immunity. Here, we review the functions of PD-L1 expressed by immune cells in the context of CD8+ T cell priming, contraction, and differentiation into memory populations, as well as the role of PD-L1 expressed by tumor cells in regulating antitumor CD8+ T cell responses.

KW - B7-H1 (programmed death-ligand 1)

KW - CTL

KW - Immunotherapy

KW - Programmed death-1:programmed death-ligand 1 blockade

KW - T cells

KW - Tumor

UR - http://www.scopus.com/inward/record.url?scp=85027275572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027275572&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00961

DO - 10.3389/fimmu.2017.00961

M3 - Review article

AN - SCOPUS:85027275572

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - AUG

M1 - 961

ER -